Schroder Investment Management Group’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $5.07M | Sell |
92,281
-75,799
| -45% | -$4.17M | ﹤0.01% | 763 |
|
2025
Q1 | $11.9M | Sell |
168,080
-50,884
| -23% | -$3.6M | 0.01% | 608 |
|
2024
Q4 | $14.4M | Buy |
218,964
+89,515
| +69% | +$5.88M | 0.01% | 586 |
|
2024
Q3 | $9.1M | Sell |
129,449
-100,150
| -44% | -$7.04M | 0.01% | 679 |
|
2024
Q2 | $18.9M | Sell |
229,599
-20,494
| -8% | -$1.69M | 0.02% | 481 |
|
2024
Q1 | $21.8M | Sell |
250,093
-20,324
| -8% | -$1.78M | 0.03% | 471 |
|
2023
Q4 | $26.1M | Buy |
270,417
+141,694
| +110% | +$13.7M | 0.03% | 426 |
|
2023
Q3 | $11.4M | Sell |
128,723
-10,082
| -7% | -$892K | 0.02% | 580 |
|
2023
Q2 | $12M | Sell |
138,805
-1,054
| -0.8% | -$91.4K | 0.02% | 588 |
|
2023
Q1 | $13.6M | Buy |
139,859
+876
| +0.6% | +$85.2K | 0.02% | 562 |
|
2022
Q4 | $14.4M | Buy |
138,983
+30,867
| +29% | +$3.19M | 0.02% | 543 |
|
2022
Q3 | $9.17M | Buy |
108,116
+95,959
| +789% | +$8.13M | 0.02% | 630 |
|
2022
Q2 | $1.01M | Buy |
12,157
+5,194
| +75% | +$430K | ﹤0.01% | 1071 |
|
2022
Q1 | $542K | Buy |
6,963
+2,041
| +41% | +$159K | ﹤0.01% | 1211 |
|
2021
Q4 | $435K | Buy |
4,922
+95
| +2% | +$8.4K | ﹤0.01% | 1136 |
|
2021
Q3 | $373K | Sell |
4,827
-283
| -6% | -$21.9K | ﹤0.01% | 1246 |
|
2021
Q2 | $427K | Buy |
5,110
+1,170
| +30% | +$97.8K | ﹤0.01% | 1242 |
|
2021
Q1 | $298K | Buy |
3,940
+77
| +2% | +$5.82K | ﹤0.01% | 1292 |
|
2020
Q4 | $338K | Sell |
3,863
-78
| -2% | -$6.83K | ﹤0.01% | 1249 |
|
2020
Q3 | $295K | Sell |
3,941
-342
| -8% | -$25.6K | ﹤0.01% | 1148 |
|
2020
Q2 | $528K | Sell |
4,283
-535
| -11% | -$66K | ﹤0.01% | 995 |
|
2020
Q1 | $398K | Buy |
+4,818
| New | +$398K | ﹤0.01% | 1011 |
|
2013
Q3 | – | Sell |
-13,644
| Closed | -$761K | – | 1517 |
|
2013
Q2 | $761K | Buy |
+13,644
| New | +$761K | ﹤0.01% | 1044 |
|